Call us now:
- Welcome to RyGen Biopharma
Innovating Biologics for a Healthier Tomorrow
Developing affordable, high-quality biologics and biosimilars using advanced recombinant DNA technology. From discovery to clinical development, we accelerate innovation to expand global access to critical biologic therapies.
Global Regulatory Alignment
Strong R&D Expertise
Recombinant DNA Technology
Who We Are
A science-driven company advancing affordable biologic medicines.
RyGen Biopharma Pvt. Ltd. is a Hyderabad-based biotechnology company focused on developing affordable, high-quality biologics and biosimilars using advanced recombinant DNA technology. Our pipeline targets metabolic disorders, oncology supportive care, autoimmune diseases, osteoporosis, and haematological conditions, ensuring global compliance and improved patient access.
Global Compliance
Programs aligned with CDSCO, US FDA, and EMA requirements.
Commitment
Delivering life-saving biologics with quality, affordability, and accessibility focus.
Our Product Portfolio
RyGen Biopharma offers a diverse portfolio of biologics and recombinant solutions designed to improve healthcare outcomes and support advanced bioprocessing needs.
Therapeutic products
RyGen Biopharma’s therapeutic product portfolio includes GLP-1 receptor agonists, insulin, and insulin analogues for metabolic disorders, along with specialty biologics such as Peg-Filgrastim for oncology supportive care, Anakinra for autoimmune conditions, Parathyroid Hormone (PTH) for osteoporosis, and Romiplostim for haematological disorders.
Recombinant enzymes
RyGen Biopharma develops high-purity recombinant enzymes used in bioprocessing, analytical workflows, and research applications. Our enzyme portfolio includes Carboxypeptidase-B, Enterokinase, and Trypsin, designed to support protein purification, cleavage processes, and downstream processing requirements across biotechnology, pharmaceutical, and laboratory environments worldwide.
- Research & Development Excellence
Our Capabilities
RyGen Biopharma offers strong scientific and operational capabilities across the biologics development lifecycle.
Cell Line & Clone Development
We develop stable, high-producing cell lines and clones using advanced screening methods to ensure consistent biologic expression and quality.
Analytical Characterization & Bioassays
We perform detailed analytical testing and bioassays to confirm identity, purity, potency, stability, and biosimilar comparability requirements.
Upstream / Downstream Process Development
We optimize fermentation and purification processes to improve yield, scalability, and product consistency while meeting global manufacturing standards.
Why Choose Us
RyGen Biopharma is a research-driven biotechnology company dedicated to developing affordable, high-quality biologics and biosimilars using advanced recombinant DNA technology.
Science-Driven Innovation
RyGen Biopharma develops biologics and biosimilars using advanced recombinant DNA technology and modern R&D expertise.
Committed to Quality & Compliance
Our programs follow global regulatory expectations ensuring quality, safety, data integrity, and regulatory readiness.
End-to-End Biologics Expertise
From cell line development to analytical characterization, we deliver complete biologics development and optimization support.
Clients & Collaborations
RyGen Biopharma collaborates with pharmaceutical companies, biotech firms, research institutions, and healthcare organizations across India and global markets to advance biologics from development to commercialization. Our partnerships include technology transfer, product development, analytical and process support, and manufacturing assistance
We work with preclinical CROs for toxicology studies and clinical CROs for upcoming trials aligned with global regulatory standards.